Thymoglobulin and an Unexpected Outbreak of Epstein-Barr Virus  by Mohty, Mohamad & Malard, Florent
Letters to the Editor / Biol Blood Marrow Transplant 21 (2015) 196e198198malignancies who lack conventional donors is well tolerated and pro-
duces excellent relapse-free survival: results of a prospective phase II
trial. Biol Blood Marrow Transplant. 2012;18:1859-1866.
6. Grosso D, Carabasi M, Filicko-O’Hara J, et al. A two-step approach to
myeloablative haploidentical stem cell transplantation: a phase I/II trial
performed with optimised T-cell dosing. Blood. 2011;118:4732-4739.
7. Brunstein CG, Fuchs EJ, Carter SL, et al. Alternative donor transplantation
after reduced intensity conditioning: results of parallel phase 2 trialsFinancial disclosure: See Acknowledgments on page 198.
* Correspondence and reprint requests: Mohamad Mohty, MD, PhD,
Department of Hematology, Hopital Saint Antoine, 184 Rue du Faubourg
Saint Antoine, 75571 Paris, France.
E-mail address: mohamad.mohty@inserm.fr (M. Mohty)
1083-8791/$ e see front matter  2015 American Society for Blood and
Marrow Transplantation.
http://dx.doi.org/10.1016/j.bbmt.2014.11.004using partially HLA-mismatched related bone marrow or unrelated
double umbilical cord blood grafts. Blood. 2011;118:282-288.
8. Kanakry C, O’Donnell P, Furlong T, et al. Multi-institutional study of post-
transplantation cyclophosphamide as single-agent graft-versus-host
disease prophylaxis after allogeneic bone marrow transplantation using
myeloablative busulfan and ﬂudarabine conditioning. J Clin Oncol. 2014;
32:3497-3505.Thymoglobulin and an Unexpected
of Epstein-Barr VirusOutbreakMohamad Mohty*, Florent Malard
Service d’Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, Paris, France
Université Pierre et Marie Curie, Paris, FranceArticle history:
Received 5 November 2014
Accepted 5 November 2014To the Editor:
In a recent issue of this journal, Yanez et al. [1] reported an
unexpected outbreak of Epstein-Barr virus (EBV) post-
transplantation lymphoproliferative disorder (PTLD) after
allogeneic hematopoietic stem cell transplantation (allo-
HSCT) conditioning with Thymoglobulin (Genzyme-Sanoﬁ,
Lyon, France). Although we agree with the authors’ conclu-
sion that antithymocyte globulin is a complex biological
agent with broad immune effects [2] and some yet unre-
solved questions, such as the best regimen, schedule, and
dose, we believe that their observation about a so-called
unexpected outbreak of EBV PTLD is weak and their claims
are not substantiated by the little data presented.
EBV PTLD is a serious complication that usually occurs in a
state of profound immunosuppression. After allo-HSCT, EBV
reactivation and EBV-related proliferations are well-
recognized complications. EBV reactivation may be associ-
ated with a spectrum of clinical presentations, from fever to
lymphoproliferative disease, which arise as a consequence of
an outgrowth of B cells latently infected with EBV in the
setting of loss or suppression of normal cytotoxic T cell sur-
veillance. Risk factors for EBV-related complications include
manipulation of the graft to deplete T cells, degree and
duration of immunosuppression used to prevent and treat
graft-versus-host disease, and degree of mismatch between
donor and recipient [3]. Interestingly, Yanez et al. [1]
acknowledged in their series a higher percentage of patients
who underwent transplantation with a mismatched donor,
which is a major risk factor for graft-versus-host disease and
its corollary of multiple lines of immunosuppressive agents
[4]. Indeed, patients who develop EBV PTLD are usually
severely immunosuppressed while receiving high-dose
corticosteroid therapy at time of EBV PTLD occurrence.
At present, it is also well established that regular and
close DNA-PCR screening for EBV reactivation is mandatoryafter allo-HSCT, and preemptive treatment with rituximab
should be started as soon as the EBV DNA level exceeds the
standard institutional threshold. With such a strategy of
preemptive treatment of EBV reactivation, the incidence of
EBV PTLD can be signiﬁcantly reduced [3]. From the report by
Yanez et al., it appears that this group does not routinely use
such a preemptive approach.
Finally, from a methodological standpoint, the interpre-
tation of Yanez et al.’s observation [1] deserves some caution.
In fact, for determining whether a parameter is causally
related to a given disease or complication, scientists have
established some rigorous guidelines [5]. According to Hill’s
criteria, evidence for causality depends on (1) strength of
association, (2) speciﬁcity, (3) temporality, (4) consistency/
reproducibility, (5) biologic gradient, (6) biologic plausibility,
and (7) experimental evidence [5]. Unfortunately, the obser-
vation by Yanez et al. [1] does not fulﬁll most of these criteria.
In the 30 years since the rabbit antithymocyte globulin,
Thymoglobulin (Genzyme-Sanoﬁ), as ﬁrst licensed, its use in
solid organ transplantation and hematology continues to in-
crease signiﬁcantly worldwide. Over time, clinicians have
learned how to better balance the beneﬁts and risks associated
with this product. Thus, despite its longhistory, Thymoglobulin
(Genzyme-Sanoﬁ) will remain a key component of the immu-
nosuppressive armamentarium in theallo-HSCTsetting, and its
complex immunological properties indicate that its use will
continue to expand to awider rangeofdisease conditions in the
future.
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